Aclaris are the new owners of Rhofade

News today that the previous owners of the intellectual property that spawned the product we know as Rhofade, have purchased the rights to buy it back from Allergan. So those responsible for creating the company that originally created the oxymetazoline based topical, and then sold it to Allergan in 2011 are now purchasing the product back again.

The deal is worth $65m, and will see Aclaris become the owners of Rhofade, its patents and worldwide distribution. Another unnamed dermatology product is also included in the transfer.

Rhofade has been available since 2017 and had in general received good reviews online. The article claims that the last of the patents protecting Rhofade will only expire in 2035.

Rosacea Market is busy

Along with the possible sale of Galderma and the sale of Finacea to Leo Pharma, there is certainly a lot happening in the rosacea market.

Given that Rhofade appears to be a successful product the question remains as to why Allergan no longer wants to keep Rhofade in its extensive product portfolio.

Press Release

Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE from Allergan

WAYNE, Pa., Oct. 15, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology and immunology, today announced it has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to RHOFADE® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property.

The acquisition includes an exclusive license to certain intellectual property for RHOFADE, which is approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

This transaction, which is subject to customary closing conditions, including certain governmental regulatory clearances, is expected to close in the fourth quarter of 2018. Allergan has agreed to provide support to Aclaris to allow for a smooth transition of RHOFADE.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

2 Reader Comments

  1. John says:

    Why would Allergan want to sell Rhofade???

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.